A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer | MicrobiomeTrials← Back to trialsNCT07652073
A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-15Est. Completion: 2027-11-30
Enrollment target: 30 participants Locations- Research site, Guangzhou, Guangdong, China
- Research site, Beijing, China
Other microbiome trials you might be interested in
Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, to…
Birmingham, United StatesEst. completion Oct 26, 2021
Acinar Cell CarcinomaAdenoid Cystic CarcinomaAdrenal Cortical CarcinomaAdrenal Gland PheochromocytomaAnal Canal Neuroendocrine CarcinomaAnal Canal Undifferentiated CarcinomaAngiosarcomaApocrine Neoplasm
Appendix Mucinous Adenocarcinoma
Bartholin Gland Transitional Cell Carcinoma
Basal Cell Carcinoma
Bladder Adenocarcinoma
Breast Metaplastic Carcinoma
Cervical Adenocarcinoma
Cholangiocarcinoma
Chordoma
Colorectal Squamous Cell Carcinoma
Desmoid Fibromatosis
Endometrial Transitional Cell Carcinoma
Endometrioid Adenocarcinoma
Esophageal Neuroendocrine Carcinoma
Esophageal Undifferentiated Carcinoma
Extrahepatic Bile Duct Carcinoma
Extramammary Paget Disease
Fallopian Tube Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Fibromyxoid Tumor
Gallbladder Carcinoma
Gastric Neuroendocrine Carcinoma
Gastric Squamous Cell Carcinoma
Gastric Undifferentiated Carcinoma
Gastrointestinal Stromal Tumor
Gestational Trophoblastic Tumor
Giant Cell Carcinoma
Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
Intestinal Neuroendocrine Carcinoma
Intrahepatic Cholangiocarcinoma
Lung Neuroendocrine Tumor
Lung Sarcomatoid Carcinoma
Major Salivary Gland Carcinoma
Malignant Neoplasm of Unknown Primary
Malignant Odontogenic Neoplasm
Malignant Peripheral Nerve Sheath Tumor
Malignant Solid Neoplasm
Malignant Testicular Sex Cord-Stromal Tumor
Metastatic Pituitary Neuroendocrine Tumor
Minimally Invasive Lung Adenocarcinoma
Mixed Mesodermal (Mullerian) Tumor
Mucinous Adenocarcinoma
Mucinous Cystadenocarcinoma
Nasal Cavity Adenocarcinoma
Nasal Cavity Carcinoma
Nasopharyngeal Carcinoma
Nasopharyngeal Low Grade Papillary Adenocarcinoma
Nasopharyngeal Undifferentiated Carcinoma
Oral Cavity Carcinoma
Oropharyngeal Undifferentiated Carcinoma
Ovarian Adenocarcinoma
Ovarian Germ Cell Tumor
Ovarian Mucinous Adenocarcinoma
Ovarian Squamous Cell Carcinoma
Ovarian Transitional Cell Carcinoma
Pancreatic Acinar Cell Carcinoma
Pancreatic Neuroendocrine Carcinoma
Paraganglioma
Paranasal Sinus Adenocarcinoma
Paranasal Sinus Carcinoma
Parathyroid Gland Carcinoma
PEComa
Penile Squamous Cell Carcinoma
Peritoneal Mesothelial Neoplasm
Placental Choriocarcinoma
Primary Peritoneal High Grade Serous Adenocarcinoma
Pseudomyxoma Peritonei
Rare Disorder
Scrotal Squamous Cell Carcinoma
Seminal Vesicle Adenocarcinoma
Seminoma
Serous Cystadenocarcinoma
Small Intestinal Adenocarcinoma
Small Intestinal Squamous Cell Carcinoma
Spindle Cell Neoplasm
Teratoma With Somatic-Type Malignancy
Testicular Non-Seminomatous Germ Cell Tumor
Thyroid Gland Carcinoma
Tracheal Carcinoma
Transitional Cell Carcinoma
Ureter Adenocarcinoma
Ureter Squamous Cell Carcinoma
Urethral Adenocarcinoma
Urethral Squamous Cell Carcinoma
Vaginal Adenocarcinoma
Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Vulvar Carcinoma
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclona…
Birmingham, United StatesEst. completion May 1, 2026